Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03539887 · ClinicalTrials.gov registry record · Phase 3
Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse
A Phase 3 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 3
- Development phase
- 33
- Enrollment target
NCT03539887 is a Phase 3 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 33 participants.
The verdict
NCT03539887, a Phase 3 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 33 participants
- Enrollment target
Study Summary
This project aims to evaluate the potential rapid and sustained antisuicidal and antidepressant effects of a single intranasal dose of ketamine in inpatients during a mood episode in Major Depressive Disorder (MDD) or Bipolar Disorder (BD) with or without comorbid recent abuse of alcohol.
Interventions
- DRUG Placebo
- DRUG Intranasal ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2022-01-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03539887
The ClinicalTrials.gov registry entry for NCT03539887 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03539887 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03539887 about?
NCT03539887 is a clinical study titled "Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse". This project aims to evaluate the potential rapid and sustained antisuicidal and antidepressant effects of a single intranasal dose of ketamine in inpatients during a mood episode in Major Depressive Disorder (MDD) or Bipolar Disorder (BD) with or without comorbid recent abuse of alcohol.
What is the current status of trial NCT03539887?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 33 participants. The study started on 2018-05-01. Estimated completion is 2022-01-15.
What interventions are being tested in trial NCT03539887?
The interventions under investigation include: Placebo (DRUG), Intranasal ketamine (DRUG).
Who is sponsoring clinical trial NCT03539887?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.